Please login to the form below

Not currently logged in
Email:
Password:

Pfizer considers Icagen options

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in.

In a regulatory filing, Pfizer said Icagen representatives and Pfizer employees have engaged in preliminary discussions, and that Icagen had provided access to due diligence materials.

Pfizer said the continuing talks could lead to an extension or amendment of their longstanding agreement, including a change in its control "by means of a stock or asset acquisition or merger."

Icagen acknowledged that it is engaged in preliminary discussions with Pfizer, however, said there can be no assurance any agreement will be reached.

In 2007 Pfizer forged a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders.

27th June 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics